A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.
Also called NCT01712061
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 226 participants
- Sponsor
- Registry
-
NCT01712061 -
2012-003332-23
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Canada, Germany, Hong Kong SAR China, Italy, Malaysia, Peru, Poland, Puerto Rico, Romania, South Korea, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01712061. Randomized; double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2015-10-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- PF-04634817
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01712061- Content hash
b675c4b330e2c6b7e1cbd8c0a1d5a67d869285e61c6ebd3937f59109945f50cb